Spyre Therapeutics, Inc.
SYRE
$16.67
$0.784.91%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 23.61% | 16.54% | 77.76% | 103.45% | 81.00% |
Total Receivables | -- | -- | -- | 942.94% | -- |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | -10.15% | -41.19% | 139.27% | 135.57% | 237.99% |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | -- | -- | -- | -- | -- |
Total Current Assets | 23.66% | 16.93% | 78.16% | 104.46% | 81.64% |
|
|||||
Total Current Assets | 23.66% | 16.93% | 78.16% | 104.46% | 81.64% |
Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | -- | -96.96% | -96.98% | -99.24% | -75.06% |
Total Assets | 23.57% | 16.85% | 77.99% | 103.16% | 79.06% |
|
|||||
Total Accounts Payable | 14.89% | 18.77% | -25.67% | 207.81% | 13.21% |
Total Accrued Expenses | 106.93% | -41.73% | -6.49% | -7.62% | -66.54% |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Liabilities | 530.32% | 1,651.27% | 1,288.92% | 38.01% | -95.17% |
Total Other Current Liabilities | 530.32% | 1,651.27% | 1,288.92% | 38.01% | -95.17% |
Total Current Liabilities | 275.46% | 65.07% | 69.05% | 28.23% | -90.47% |
|
|||||
Total Current Liabilities | 275.46% | 65.07% | 69.05% | 28.23% | -90.47% |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | -- | -94.36% | -70.91% | 74.77% | 85.37% |
Total Liabilities | 34.66% | -74.01% | -42.55% | 42.92% | -75.68% |
|
|||||
Common Stock & APIC | 26.94% | 73.11% | 74.82% | 138.23% | 134.98% |
Retained Earnings | -24.41% | -25.85% | -27.21% | -30.65% | -28.13% |
Treasury Stock & Other | 182.10% | 287.88% | -40.40% | 1,203.79% | -5,127.27% |
Total Common Equity | 37.24% | 1,100.64% | 39,834.80% | 169.91% | 205.40% |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | 0.00% | -15.74% | -15.74% | -59.75% | -21.03% |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | 0.00% | -15.74% | -15.74% | -59.75% | -21.03% |
|
|||||
Total Common Equity | 37.24% | 1,100.64% | 39,834.80% | 169.91% | 205.40% |
Total Preferred Equity | 0.00% | -15.74% | -15.74% | -59.75% | -21.03% |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 21.74% | 216.95% | 181.39% | 131.04% | 3,826.71% |
|